The short answer
Echinacea may affect a liver enzyme involved in clearing ropinirole, but studies with other test drugs have differing results. Increased ropinirole absorption or blood levels have not been demonstrated. Ask your pharmacist to review the species, plant part and preparation before use.
What this answer covers
Echinacea purpurea root and a separately studied E. purpurea extract; other species, plant parts and combination products are not equivalent.
- Supplement or preparation
- Echinacea purpurea
- Medication ingredient
- ropinirole
The study suggesting an effect
Twelve healthy adults took an E. purpurea root product for eight days. Caffeine, used as a test drug, was cleared more slowly. Because ropinirole uses the same liver enzyme, this is a reason to review the combination, not a measurement of ropinirole levels.
The study that limits the conclusion
Another small study examined a different E. purpurea extract over 28 days and found no statistically significant change in the enzyme measurements. Preparation and testing methods differed, so neither result should be applied to every bottle of echinacea.
Absorption and clearance are different
Slower liver clearance can raise a drug level without increasing how much enters from the gut. These studies do not demonstrate that echinacea increases ropinirole absorption, and the effects measured with other drugs cannot supply a ropinirole dose adjustment.
How to handle a planned change
Tell your pharmacist or prescriber before starting or stopping the supplement, and bring the product label. Report a clear change in symptom control or side effects. These sources do not establish a protective spacing interval or a standard ropinirole dose adjustment for this supplement.
Evidence and practical considerations
Absorption & effectiveness
Human E. purpurea enzyme-probe findings differ between studies; a clinically important increase in ropinirole exposure remains uncertain.
- Exact scope
- Echinacea purpurea root and a separately studied E. purpurea extract; other species, plant parts and combination products are not equivalent. with Oral immediate-release ropinirole; hydrochloride salt expressed as equivalent free base in the inspected label.
- Medication form and route
- oral ropinirole; supplement preparation and route described in scope
- Timing or duration
- No exact-pair safe duration or protective spacing interval established.
What remains uncertain
- Neither study administered ropinirole. Different products, durations and probe methods preclude a uniform clinical effect.
Factors that may matter: species and plant part; duration of use; extract composition.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral immediate-release ropinirole tablets for Parkinson disease or primary restless legs syndrome.
Ropinirole can cause somnolence, sudden sleep episodes and orthostatic hypotension. Concomitant sedating medicines or alcohol can increase sleepiness risk. CYP1A2 is its major metabolic enzyme; inhibitors and inducers may alter clearance. Ciprofloxacin increased exposure, whereas theophylline did not. Cigarette smokers had lower dose-normalized exposure than nonsmokers in a small RLS comparison.
How this applies: Exact oral ropinirole risk and metabolic context; section 11 justifies hydrochloride-to-free-base active-moiety identity only.
None of these ten supplement pairs is directly tested in this label. Cigarette smoking is not interchangeable with oral cannabis or isolated CBD; ciprofloxacin results are not caffeine results. No extended-release kinetic equivalence assumed.
Source 2: open-label fixed-sequence enzyme-probe study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 12 healthy adults, including six men.
Caffeine oral clearance fell from 6.6 to 4.9 L/hour. Intestinal and hepatic CYP3A effects differed.
How this applies: Possible CYP1A2 inhibition; does not demonstrate increased ropinirole absorption or specify an adjustment.
Caffeine and midazolam were probes, not ropinirole. Root product, eight days and substantial interindividual variability limit generalization.
Source 3: randomized-sequence botanical enzyme-phenotyping study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 12 healthy adults, six women and six men.
No statistically significant change in measured CYP1A2, CYP2D6, CYP2E1 or CYP3A4 phenotypic ratios. Authors considered the Echinacea effects minor but meriting further study.
How this applies: Limits an assumption that all E. purpurea products meaningfully inhibit ropinirole clearance.
Small sample, single-time-point probe ratios and a particular product; not a ropinirole trial. Different preparation, duration and method from the root study.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources inspected and exact current claim adjudicated; no clinical review asserted. | |
| Research summary published |
Article revision: e5e9f71aeed2c502
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.